Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Published:2020-02 Issue:2 Volume:21 Page:242-249
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hashimoto Hironobu,Abe Masakazu,Tokuyama Osamu,Mizutani Hideaki,Uchitomi Yosuke,Yamaguchi Takuhiro,Hoshina Yukari,Sakata Yasuhiko,Takahashi Takako Yanai,Nakashima Kazuhisa,Nakao Masahiko,Takei Daisuke,Zenda Sadamoto,Mizukami Koki,Iwasa Satoru,Sakurai Michiru,Yamamoto Noboru,Ohe Yuichiro

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Proposal for Classifying the acute emetogenicity of cancer chemotherapy;Hesketh;J Clin Oncol,1997

2. A randomized phase III study evaluating the efficacy and safety of NEPA, a fix-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy;Aapro;Ann Oncol,2014

3. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3(Alliance);Barton;Cancer,2014

4. Radioreceptor binding profile of the atypical antipsychotic olanzapine;Bymaster;Neuropsychopharmacology,1996

5. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding;Schotte;Psychopharmacology,1996

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis;Frontiers in Pharmacology;2024-09-13

3. A Fact-Finding Survey of the Concerns of Patients with Cancer: A Network Analysis;2024-09-10

4. Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: A systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology;2024-09-08

5. Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success;Critical Reviews in Oncology/Hematology;2024-09